Global Thalassemia Treatment Market to Reach $1.8 Billion by 2030
The global market for Thalassemia Treatment estimated at US$1.1 Billion in the year 2022, is projected to reach a revised size of US$1.8 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2022-2030. Blood Transfusion, one of the segments analyzed in the report, is projected to record 6.5% CAGR and reach US$511.1 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chelating Therapy segment is readjusted to a revised 6.9% CAGR for the next 8-year period.The U.S. Market is Estimated at $327.5 Million, While China is Forecast to Grow at 6.1% CAGR
The Thalassemia Treatment market in the U.S. is estimated at US$327.5 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$313.6 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6% and 5.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.Select Competitors (Total 13 Featured) -
- Acceleron Pharma, Inc.
- Bellicum Pharmaceuticals, Inc.
- bluebird bio, Inc.
- Celgene Corporation
- Gamida Cell Ltd.
- Incyte Corporation
- Kiadis Pharma N.V.
- Novartis AG
- Shire PLC
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Acceleron Pharma, Inc.
- Bellicum Pharmaceuticals, Inc.
- bluebird bio, Inc.
- Celgene Corporation
- Gamida Cell Ltd.
- Incyte Corporation
- Kiadis Pharma N.V.
- Novartis AG
- Shire PLC
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 182 |
Published | May 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 1.1 Billion |
Forecasted Market Value ( USD | $ 1.8 Billion |
Compound Annual Growth Rate | 6.3% |
Regions Covered | Global |